Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium

Background: It is not known whether modifiable lifestyle factors that predict survival after invasive breast cancer differ by subtype. Methods: We analyzed data for 121,435 women diagnosed with breast cancer from 67 studies in the Breast Cancer Association Consortium with 16,890 deaths (8,554 breast cancer specific) over 10 years. Cox regression was used to estimate associations between risk factors and 10-year all-cause mortality and breast cancer–specific mortality overall, by estrogen receptor (ER) status, and by intrinsic-like subtype. Results: There was no evidence of heterogeneous associations between risk factors and mortality by subtype (Padj > 0.30). The strongest associations were between all-cause mortality and BMI ≥30 versus 18.5–25 kg/m2 [HR (95% confidence interval (CI), 1.19 (1.06–1.34)]; current versus never smoking [1.37 (1.27–1.47)], high versus low physical activity [0.43 (0.21–0.86)], age ≥30 years versus <20 years at first pregnancy [0.79 (0.72–0.86)]; >0–<5 years versus ≥10 years since last full-term birth [1.31 (1.11–1.55)]; ever versus never use of oral contraceptives [0.91 (0.87–0.96)]; ever versus never use of menopausal hormone therapy, including current estrogen–progestin therapy [0.61 (0.54–0.69)]. Similar associations with breast cancer mortality were weaker; for example, 1.11 (1.02–1.21) for current versus never smoking. Conclusions: We confirm associations between modifiable lifestyle factors and 10-year all-cause mortality. There was no strong evidence that associations differed by ER status or intrinsic-like subtype. Impact: Given the large dataset and lack of evidence that associations between modifiable risk factors and 10-year mortality differed by subtype, these associations could be cautiously used in prognostication models to inform patient-centered care.

S. Cross | M. Beckmann | P. Fasching | A. Olshan | N. Camp | D. Noh | C. Vachon | Jingmei Li | K. Czene | P. Hall | F. Couch | A. Schneeweiss | H. Brenner | J. Chang-Claude | S. Chanock | M. García-Closas | D. Hunter | A. Wolk | H. Becher | G. Giles | J. Hopper | C. Haiman | T. Dörk | M. Southey | A. Cox | D. Easton | P. Kraft | R. Tamimi | G. Rennert | Chen-Yang Shen | D. Lambrechts | L. Le Marchand | D. Stram | V. Kristensen | X. Shu | W. Zheng | A. Ziogas | H. Anton-Culver | P. Guénel | A. Dunning | D. Eccles | D. Evans | S. Bojesen | B. Nordestgaard | D. Kang | K. Yoo | R. Tollenaar | R. Milne | U. Hamann | A. Mannermaa | M. Shah | C. Clarke | A. Lindblom | M. Schmidt | M. Bolla | Qin Wang | T. Muranen | C. Blomqvist | H. Flyger | T. Truong | E. Sawyer | I. Tomlinson | S. Margolin | A. Jager | V. Arndt | R. Winqvist | M. Grip | A. Jakubowska | J. Lubiński | K. Matsuo | Hidemi Ito | A. Wu | S. Teo | M. Hartman | P. Pharoah | K. Egan | T. Park-Simon | D. Torres | M. Dwek | W. Tapper | M. Lush | D. Campa | F. Canzian | W. Newman | S. Gapstur | R. Kaaks | R. Keeman | Jyh‐cherng Yu | S. Hart | J. Lacey | M. U. Rashid | M. Troester | D. Plaseska-Karanfilska | W. Janni | A. Jung | M. Manoochehri | S. Brucker | Stella Koutros | J. García-Saenz | Sophia S. Wang | Sileny N. Han | N. Obi | H. Rennert | J. Heyworth | Christopher Scott | S. Mariapun | N. Håkansson | M. Gago-Domínguez | J. Castelao | Ji-Yeob Choi | C. Kitahara | H. Olsson | M. Gaudet | L. Schwentner | A. Romero | T. Ahearn | P. Auvinen | L. B. Beane Freeman | S. Behrens | A. Eliassen | M. Jakimovska | D. Mavroudis | N. Presneau | V. Rhenius | E. Saloustros | Xiaohong R. Yang | I. Briceño | P. Kapoor | A. Morra | M. Holmes | C. Petridis | A. Augustinsson | Reiner Hoppe | J. E. Castelao | Justin A. Williams | Thérèse Truong | M. Holmes | P. Hall | Mervi Grip | D. Evans | D. Hunter | Qin Wang | Thérèse Truong | A. Wu | D. Plaseska‐Karanfilska | Diana Torres | D. Evans

[1]  C. Friedenreich,et al.  Physical Activity and Mortality in Cancer Survivors: A Systematic Review and Meta-Analysis , 2019, JNCI cancer spectrum.

[2]  J. Chang-Claude,et al.  Pre- to postdiagnosis leisure-time physical activity and prognosis in postmenopausal breast cancer survivors , 2019, Breast Cancer Research.

[3]  V. Beral,et al.  Menopausal hormone therapy and 20-year breast cancer mortality , 2019, The Lancet.

[4]  Paul Madley-Dowd,et al.  The proportion of missing data should not be used to guide decisions on multiple imputation , 2019, Journal of clinical epidemiology.

[5]  Ruth M Pfeiffer,et al.  Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population , 2018, Breast Cancer Research.

[6]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[7]  P. Bernard,et al.  Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer , 2017, Cancer.

[8]  Si-ying Zhou,et al.  Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies , 2017, Breast Cancer.

[9]  Suyun Li,et al.  Smoking and survival of breast cancer patients: A meta-analysis of cohort studies. , 2017, Breast.

[10]  W. Willett,et al.  Cigarette Smoking Before and After Breast Cancer Diagnosis: Mortality From Breast Cancer and Smoking-Related Diseases. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Kauczor,et al.  Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study , 2016, BMC Cancer.

[12]  J. Chang-Claude,et al.  Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort , 2015, International journal of cancer.

[13]  R. Wolff,et al.  Pre-diagnostic breastfeeding, adiposity, and mortality among parous Hispanic and non-Hispanic white women with invasive breast cancer: the Breast Cancer Health Disparities Study , 2016, Breast Cancer Research and Treatment.

[14]  Charles M. Perou,et al.  Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy , 2015, BMC Medicine.

[15]  M. Bracken,et al.  Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. , 2015, Journal of the National Cancer Institute.

[16]  A. Olshan,et al.  Association of Parity and Time since Last Birth with Breast Cancer Prognosis by Intrinsic Subtype , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[17]  I. Stijleman,et al.  Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival. , 2015, Journal of the National Cancer Institute.

[18]  A. McTiernan,et al.  Body mass index and survival in women with breast cancer—systematic literature review and meta-analysis of 82 follow-up studies , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  L. Holmberg,et al.  Recent childbirth is an adverse prognostic factor in breast cancer and melanoma, but not in Hodgkin lymphoma. , 2013, European journal of cancer.

[20]  Lihong Qi,et al.  Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. , 2013, Journal of the National Cancer Institute.

[21]  C. Shimizu,et al.  Impact of recent parity on histopathological tumor features and breast cancer outcome in premenopausal Japanese women , 2013, Breast Cancer Research and Treatment.

[22]  C. Smee,et al.  United Kingdom , 2000, International Journal of Pharmaceutical Medicine.

[23]  L. Vatten,et al.  Association of time since last birth, age at first birth and parity with breast cancer survival among parous women: A register‐based study from Norway , 2013, International journal of cancer.

[24]  Patrick Neven,et al.  Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. , 2011, Human molecular genetics.

[25]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  B. Strom,et al.  Oral Contraceptive Use and Survival in Women with Invasive Breast Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[27]  Victoria L. Cafourek,et al.  Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. , 2011, Journal of the National Cancer Institute.

[28]  K. Kerlikowske,et al.  Reproductive history and risk of three breast cancer subtypes defined by three biomarkers , 2011, Cancer Causes & Control.

[29]  J. Manson,et al.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.

[30]  G. Giles,et al.  Prediagnosis Reproductive Factors and All-Cause Mortality for Women with Breast Cancer in the Breast Cancer Family Registry , 2009, Cancer Epidemiology Biomarkers & Prevention.

[31]  D. Easton,et al.  Risk factors for the incidence of breast cancer: do they affect survival from the disease? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  P. Hall,et al.  Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study , 2008, Breast Cancer Research.

[33]  Jason Hsia,et al.  Oral Contraceptives and the Risk of Death From Breast Cancer , 2007, Obstetrics and gynecology.

[34]  R. Coates,et al.  Oral Contraceptives and Survival in Breast Cancer Patients Aged 20 to 54 Years , 2007, Cancer Epidemiology Biomarkers & Prevention.

[35]  Michael J Pencina,et al.  Choice of time scale and its effect on significance of predictors in longitudinal studies , 2007, Statistics in medicine.

[36]  D. Petitti,et al.  Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study , 2005, British Journal of Cancer.

[37]  A. Hanlon,et al.  Parity confers better prognosis in older women with early-stage breast cancer treated with breast-conserving therapy. , 2004, Clinical breast cancer.

[38]  P. Wingo,et al.  Reproductive History and Mortality After Breast Cancer Diagnosis , 2004, Obstetrics and gynecology.

[39]  G. Giles,et al.  Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  E. Franssen,et al.  Are medical oncologists biased in their treatment of the large woman with breast cancer? , 2001, Breast Cancer Research and Treatment.

[41]  L. Meurer,et al.  Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis. , 2002, The Journal of family practice.

[42]  Wendy Demark-Wahnefried,et al.  Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  G. Reeves,et al.  Hormonal and other factors in relation to survival among breast cancer patients , 2000, International journal of cancer.

[44]  A. Zauber,et al.  Relation of time since last birth and parity to survival of young women with breast cancer. , 1998, Epidemiology.

[45]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[46]  A. Lethaby,et al.  Survival of women with node negative breast cancer in the Auckland region. , 1996, The New Zealand medical journal.

[47]  P. Tartter,et al.  Reproductive history and prognosis in patients with operable breast cancer , 1994, Cancer.